FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382344892> ?p ?o ?g. }

• W4382344892 endingPage "e072363" @default.
• W4382344892 startingPage "e072363" @default.
• W4382344892 abstract "Emicizumab effectively prevents bleeding in people with haemophilia A (PwHA), but is a burden for national healthcare budgets and consequently may limit access. According to the drug label, dosing of emicizumab is based on body weight with fixed intervals of 7, 14 or 28 days, which leads to mean plasma concentrations of 55 µg/mL (SD 15 µg/mL). However, a moderate variability of concentrations and a minimal effective concentration of 30 µg/mL have been suggested in studies. Therefore, a dose of emicizumab that targets a trough concentration of 30 µg/mL is hypothesised to be equally effective as conventional dosing in the prevention of bleeding.We designed a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of bleed control of ≥6 months on conventional dosing in comparison to ≥6 months on dose intervention. This dose intervention consists of reducing the dose of emicizumab to target a trough concentrations of 30 µg/mL using individual pharmacokinetic (PK) parameters. Ninety-five PwHA aged >1 years who received conventional dosing of emicizumab for ≥12 months with good bleeding control during the last 6 months will be recruited from all Dutch haemophilia treatment centres. The study is powered to detect a clinically relevant decrease (risk difference) of 15% in the proportion of patients without treated bleeds during follow-up. Secondary endpoints are spontaneous joint or muscle bleeds, and annualised treated bleeding rates (using negative binomial regression). Cost-effectivity between conventional dosing and individualised PK-guided dosing of emicizumab will be compared.The DosEmi study was approved by the Medical Ethics Review Committee NedMec of the University Medical Center of Utrecht, The Netherlands. Study results will be communicated through publications in international scientific journals and presentations at (inter)national conferences.EUCTR2021-004039-10-NL at https://trialsearch.who.int.V.4.1 on 28 October 2022 (DosEmi protocol_V4.1; NL81112.041.22)." @default.
• W4382344892 created "2023-06-29" @default.
• W4382344892 creator A5011613259 @default.
• W4382344892 creator A5012431332 @default.
• W4382344892 creator A5021986417 @default.
• W4382344892 creator A5024588131 @default.
• W4382344892 creator A5043026808 @default.
• W4382344892 creator A5049444203 @default.
• W4382344892 creator A5061424600 @default.
• W4382344892 creator A5077378056 @default.
• W4382344892 creator A5079993239 @default.
• W4382344892 creator A5083938702 @default.
• W4382344892 date "2023-06-01" @default.
• W4382344892 modified "2023-10-16" @default.
• W4382344892 title "DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A" @default.
• W4382344892 cites W157541105 @default.
• W4382344892 cites W1902838605 @default.
• W4382344892 cites W1952640046 @default.
• W4382344892 cites W2003240945 @default.
• W4382344892 cites W2020123164 @default.
• W4382344892 cites W2026502021 @default.
• W4382344892 cites W2075578463 @default.
• W4382344892 cites W2123242870 @default.
• W4382344892 cites W2157542613 @default.
• W4382344892 cites W2296150002 @default.
• W4382344892 cites W2473786944 @default.
• W4382344892 cites W2535041295 @default.
• W4382344892 cites W2772289727 @default.
• W4382344892 cites W2789604711 @default.
• W4382344892 cites W2888898681 @default.
• W4382344892 cites W3016428066 @default.
• W4382344892 cites W3034093413 @default.
• W4382344892 cites W3047046471 @default.
• W4382344892 cites W3086115407 @default.
• W4382344892 cites W3115183047 @default.
• W4382344892 cites W3131214176 @default.
• W4382344892 cites W3134537625 @default.
• W4382344892 cites W3157693370 @default.
• W4382344892 cites W3168986511 @default.
• W4382344892 cites W3187789458 @default.
• W4382344892 cites W3196335108 @default.
• W4382344892 cites W3197167619 @default.
• W4382344892 cites W3200745831 @default.
• W4382344892 cites W3212036572 @default.
• W4382344892 cites W3217674572 @default.
• W4382344892 cites W4205236146 @default.
• W4382344892 cites W4206422429 @default.
• W4382344892 cites W4220880186 @default.
• W4382344892 cites W4229019465 @default.
• W4382344892 cites W4281630688 @default.
• W4382344892 cites W4281644414 @default.
• W4382344892 cites W4310467648 @default.
• W4382344892 cites W4319455727 @default.
• W4382344892 doi "https://doi.org/10.1136/bmjopen-2023-072363" @default.
• W4382344892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37369395" @default.
• W4382344892 hasPublicationYear "2023" @default.
• W4382344892 type Work @default.
• W4382344892 citedByCount "0" @default.
• W4382344892 crossrefType "journal-article" @default.
• W4382344892 hasAuthorship W4382344892A5011613259 @default.
• W4382344892 hasAuthorship W4382344892A5012431332 @default.
• W4382344892 hasAuthorship W4382344892A5021986417 @default.
• W4382344892 hasAuthorship W4382344892A5024588131 @default.
• W4382344892 hasAuthorship W4382344892A5043026808 @default.
• W4382344892 hasAuthorship W4382344892A5049444203 @default.
• W4382344892 hasAuthorship W4382344892A5061424600 @default.
• W4382344892 hasAuthorship W4382344892A5077378056 @default.
• W4382344892 hasAuthorship W4382344892A5079993239 @default.
• W4382344892 hasAuthorship W4382344892A5083938702 @default.
• W4382344892 hasBestOaLocation W43823448921 @default.
• W4382344892 hasConcept C112705442 @default.
• W4382344892 hasConcept C126322002 @default.
• W4382344892 hasConcept C142724271 @default.
• W4382344892 hasConcept C187212893 @default.
• W4382344892 hasConcept C204787440 @default.
• W4382344892 hasConcept C27081682 @default.
• W4382344892 hasConcept C2777232031 @default.
• W4382344892 hasConcept C2777288759 @default.
• W4382344892 hasConcept C2778385053 @default.
• W4382344892 hasConcept C71924100 @default.
• W4382344892 hasConcept C87813604 @default.
• W4382344892 hasConceptScore W4382344892C112705442 @default.
• W4382344892 hasConceptScore W4382344892C126322002 @default.
• W4382344892 hasConceptScore W4382344892C142724271 @default.
• W4382344892 hasConceptScore W4382344892C187212893 @default.
• W4382344892 hasConceptScore W4382344892C204787440 @default.
• W4382344892 hasConceptScore W4382344892C27081682 @default.
• W4382344892 hasConceptScore W4382344892C2777232031 @default.
• W4382344892 hasConceptScore W4382344892C2777288759 @default.
• W4382344892 hasConceptScore W4382344892C2778385053 @default.
• W4382344892 hasConceptScore W4382344892C71924100 @default.
• W4382344892 hasConceptScore W4382344892C87813604 @default.
• W4382344892 hasIssue "6" @default.
• W4382344892 hasLocation W43823448921 @default.
• W4382344892 hasLocation W43823448922 @default.
• W4382344892 hasOpenAccess W4382344892 @default.
• W4382344892 hasPrimaryLocation W43823448921 @default.
• W4382344892 hasRelatedWork W1966777365 @default.

• next